Main Article Content
Anaphylaxis is a systemic, immediate hypersensitivity reaction due to IgE mediated immunologic release of
mediators from mast cells and basophils. Features of severe condition are obstruction of the upper airway from tissue
swelling, marked bronchospasm, and hypotension. In vaccination related anaphylaxis, optimal management begins with
prevention: prevaccination screening including questions about possible allergy to any component of vaccine, and anticipation
of anaphylaxis by observation at least 15 minutes following vaccination are very important. The essential treatment is
prompt administration of adrenaline. Since hypotension is due to a shift of fluid from intravascular to extravascular space, the
mainstay of treatment should be the restoration of intravascular volume. Since anaphylaxis can be biphasic administration of
corticosteroid in preventing late phase reaction can be postulated.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
and treatment. In: Bierman CW, Pearlman DS, Shapiro GG, Busse WW, editors. Allergy, asthma and immunology from infancy to adulthood 3rd ed, Philadelphia, WB Saunders; 1996. p. 297-319.
2. Fulginiti VA. Adverse reactions to vaccines: the complexity of vaccine safety, in: Bierman CW, Pearlman DS, Shapiro GG, Busse WW, editors. Allergy asthma and immunology from infancy to adulthood 3rd ed. Philadelphia, WB Saunders 1996. p. 384-91.
3. Scheifele DW. Initial management of anaphylaxis. Vaccines: Children and practice 1999, 2:14-5.
4. Viner NA, Rhany RK. Anaphylaxis manifested by hypotension alone. J Urol 1975; 113:108-12.
5. Popa VT, Lerner SA. Biphasic systemic anaphylactic reaction. The illustrative cases. Ann Allergy 1984, 53:151-5.
6. Shine K, Kuhn M, Young L, Tillisch J. Aspects of the management of shock. Ann Intern Med 1980; 93:723-34.
7. Mueller DL, Noxon JO. Anaphylaxis: pathophysiology and treatment. The compendium 1990, 12:157-71.
8. Saryan JA, O'Louglin JM. Anaphylaxis in children. Pediatr Ann 1992, 21:590-8.
9. Yarbrough JA, Moffit JE, Brown DA, Stafford CT. Cimitidine in the treatment of refractory anaphylaxis. Ann Allergy 1989, 63:237-8.